Navigation Links
Valeant Pharmaceuticals Announces Increase to Monetary Limit Under Its Securities Repurchase Program
Date:8/29/2011

MISSISSAUGA, Ontario, Aug. 29, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (the "Company" or "Valeant") announced today that its Board of Directors has approved an increase of $300 million under its previously announced securities repurchase program (the "Securities Repurchase Program").  Under the Securities Repurchase Program, Valeant may now repurchase up to $1.8 billion of its convertible notes, senior notes, common shares and/or other notes or shares that may be issued prior to the completion of the program. As part of this Securities Repurchase Program, Valeant also recently announced that it had filed a Notice of Intention to make a normal course issuer bid to repurchase up to 1,000,000 of its common shares through the facilities of the Toronto Stock Exchange ("TSX").

The Securities Repurchase Program will terminate on November 7, 2011 or at such time as Valeant completes its purchases.  To date, the Company has purchased 14,969,599 of its common shares for aggregate consideration of $590.6 million and a total of $302.5 million principal amount of its 5.375% Convertible Notes for aggregate consideration of $806.3 million. The amount of securities to be purchased and the timing of purchases under the Securities Repurchase Program may be subject to various factors, which may include the price of the securities, general market conditions, corporate and regulatory requirements, alternate investment opportunities and restrictions under the Company's financing agreements. The securities to be repurchased will be funded using Valeant's cash resources.

Valeant believes that the proposed purchases are in the best interests of the Company and are a desirable use of corporate funds. The Securities Repurchase Program may be modified, suspended or terminated at any time without prior notice.

About Valeant Pharmaceuticals International, Inc.

Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) i
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 3SBio Inc. (NASDAQ: SSRX ... China -based biotechnology company focused on ... today that, at an extraordinary general meeting held ... favor of the proposal to authorize and approve ... dated February 8, 2013, among Decade Sunshine Limited, ...
(Date:5/23/2013)... BRAINTREE, Mass. , May 23, 2013  Haemonetics Corporation ... Chris Lindop , CFO & EVP-Business Development, will present ... Care Conference in Boston, MA on ... (Logo: http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) The public may ... About Haemonetics Haemonetics (NYSE: ...
(Date:5/23/2013)... KNOXVILLE, Tenn. , May 23, 2013 /PRNewswire/ ... of 24-hour nurse triage and nurse advice lines, ... 10-person committee, comprising physician, nursing and administrative leaders, ... providing safe, quality and cost-effective services for hospital ... "As our national healthcare system evolves, it,s imperative ...
Breaking Medicine Technology:3SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 23SBio Inc. Announces Shareholders' Approval of the Amended Merger Agreement 3TeamHealth Medical Call Center Forms Clinical Advisory Committee 2
... JERUSALEM, Israel , July 7, 2010 Oramed,Pharmaceuticals ... announced that Oramed entered into a,Manufacturing Supply Agreement (MSA) with sanofi-aventis. According ... to be used by Oramed for its clinical trials in the, USA ... ...
... 7 ITelagen, a leading provider of electronic health record ... LLC of West Windsor, NJ to host their Zweena ... its expertise in EHR management, is providing professional mission-critical hosting, security ... , , ...
Cached Medicine Technology:Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Oramed's Oral Insulin Capsules 2Oramed Pharmaceuticals and sanofi-aventis Enter Into an Agreement for the Insulin Supply of Oramed's Oral Insulin Capsules 3Zweena Selects ITelagen to Host Personal Health Records Application 2Zweena Selects ITelagen to Host Personal Health Records Application 3
(Date:5/24/2013)... According to a May 15, 2013 Time Online article ... in Plastic Surgery Requests,” a number of current ... plastic surgery and cosmetic improvements among people that ... of the need to look good online and on their ... Skype's video chat feature (Go to goo.gl/WO0PR). , “According to ...
(Date:5/24/2013)... -- The number of U.S. patients admitted to ... an emergency room has increased by nearly 50 ... conducted by researchers at the George Washington University ... Washington, D.C., found that patients wait five hours ... admitted to the ICU. The researchers said improved ...
(Date:5/24/2013)... 2013, Paris, France: Routinely measuring fractional flow reserve ... for diagnosis of chest pain leads to significant ... patients, according to results from a study reported ... pressure wire assessment influence management strategy at coronary ... designed to assess whether routine assessment of FFR ...
(Date:5/24/2013)... discovery at Oregon Health & Science University highlights an ... infected with the highly evasive HIV virus that causes ... this unique approach to develop its own HIV vaccine ... animal studies. This latest research finding will be published ... Science . , "A major challenge in ...
(Date:5/24/2013)... CBT News.com recently announced the addition of ... retail automotive industry news organization with 12 years experience in ... join a group that’s so forward-thinking in their approach,” says ... video content is on the rise.” , Atlanta born and ... segued into advertising at Cycle News and Boating World. He ...
Breaking Medicine News(10 mins):Health News:Facebook and Google – Is Social Media Driving Demand for Plastic Surgery? 2Health News:Sharp Rise in ICU Admissions From U.S. Emergency Rooms 2Health News:Diagnostic coronary angiography: Functional flow reserve changes decisions in 25 percent of cases 2Health News:OHSU research highlights promising strategy to help vaccines outsmart HIV 2
... Community Health Plan Outperforms National Medicaid Plans on ... Francisco Health Plan (SFHP), the City,s community health ... the U.S. leader in childhood immunizations for Medicaid ... members are fully immunized, besting second-ranked Kaiser Permanente ...
... 21 Couples have different reproductive plans, lifestyles, ... the array of contraceptive choices available, can make ... patients. The selection of appropriate and acceptable contraceptive ... rate of unintended pregnancy. To address this issue, ...
... Practice and Tucson Medical Center have joined forces to ... to devote to patient care. This new partnership is ... southern Arizona area better handle the cumbersome and time-consuming ... alliance, Tucson Medical Center will use Physicians Practice,s extensive ...
... a virus to thwart tumor,s comeback , , WEDNESDAY, ... group of cancer stem cells or "tumor-initiating cells" which, ... from turning malignant. , The finding bolsters the theory ... cells that are resistant to conventional therapies and responsible ...
... new study conducted at the Centre for Studies and ... and published by Elsevier in the February 2009 issue ... in confabulating patients, memory accuracy improves when attentional resources ... behavior need attentional resources for their operation. Consider memory. ...
... Technical University of Catalonia (UPC) and Universitat Autnoma de ... (ESA) to design and carry out a scientific experiment ... between drugs and cells differ under these conditions. The ... Vaquer, with a doctorate in Medicine from UAB, and ...
Cached Medicine News:Health News:San Francisco Health Plan is U.S. Leader in Childhood Immunizations 2Health News:San Francisco Health Plan is U.S. Leader in Childhood Immunizations 3Health News:Physicians Practice and Tucson Medical Center Partner to Improve Patient Care in Southern Arizona 2Health News:Physicians Practice and Tucson Medical Center Partner to Improve Patient Care in Southern Arizona 3Health News:Targeting Cancer's Own Stem Cells to Fight Recurrence 2Health News:Targeting Cancer's Own Stem Cells to Fight Recurrence 3Health News:When less attention improves behavior 2Health News:Students from UAB and UPC will experiment under microgravity conditions at the ESA 2Health News:Students from UAB and UPC will experiment under microgravity conditions at the ESA 3
Liberty Single Piece PMMA Lens with UV Absorber....
Optical implants for the replacement of the human crystalline lens in the visual correction of aphakia....
... a sterile nonpyrogenic, transparent viscoelastic solution of ... 12 mg/ml of high molecular weight (greater ... in physiological saline. In the limit of ... cps (105 Pa s) at 25 C ...
... Plus is the preferred viscoelastic for phacoemulsification ... reliably works from the start to the ... cohesive profile of this viscoelastic is the ... associated with phacoemulsification remove only a fraction ...
Medicine Products: